Published works by Parithosh K. Tungaturthi, Ph.D.

Published works

• Teva Sues FDA Alleging Unlawful Interpretation of the Definition of “First Applicant”

  BioLoquitur · October 24, 2018

  LEX-WK-VQDNX5SK
• USPTO Director Proposes New Patent Eligibility Guidance

  BioLoquitur · October 15, 2018

  LEX-WK-GG01359N
• Now Available! Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition

  BioLoquitur · April 5, 2018

  LEX-WK-6VM0KXXQ
• Good ANDA Submission Practices: Summary of Draft Guidance

  BioLoquitur · April 2, 2018

  LEX-WK-95EGSZSZ
• Innovation in Hatch-Waxman and ANDA Litigation

  BioLoquitur · March 12, 2018

  LEX-WK-7X2ET42D
• Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review

  BioLoquitur · February 8, 2018

  LEX-WK-CPKWNSYY
• 2017 Patent Litigation: A Statistical Overview

  BioLoquitur · January 17, 2018

  LEX-WK-8QNE6S20
• FDA Releases Draft Guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application

  BioLoquitur · December 4, 2017

  LEX-WK-S5PCZ3HN
• Federal Circuit Confirms That It Is Bound By Congress And Supreme Court In Its Standard Of Review Of Appeals Under The AIA

  BioLoquitur · May 3, 2016

  LEX-WK-VMBP9VNP
• Momenta v. Teva – Effective Claiming of Methods of Testing Drug Products

  BioLoquitur · December 21, 2015

  LEX-WK-3EDEFFQR
• Unraveling the Riddle, Solving the Mystery and Comprehending the Enigma: Amgen Inc. v. Sandoz Inc.

  BioLoquitur · November 3, 2015

  LEX-WK-TZ1SBX45
• Torrent v. Apotex: Secondary Indicia Insufficient to Counter Obviousness of Gilenya at PTAB

  BioLoquitur · October 13, 2015

  LEX-WK-RS98YV1P